Study: Wales has highest rate of self-medication for anxiety in the UK at 31%
By
Amelia Jones
2h ago· 4 min readenNews
Summary
A study from the STADA Health Report 2026 reveals that 31% of Welsh adults self-medicate for anxiety or stress, the highest rate of any UK region and nearly six percentage points above the national average of 25.2%. The report is published by STADA Thornton & Ross, a manufacturer of healthcare brands.
Source
bskyStudy: Wales has highest rate of self-medication for anxiety in the UK at 31%nation.cymruKey quotes
· 1 pulled31 per cent of adults in Wales self-medicate for anxiety or stress – almost six percentage points above the national average of 25.2 per cent, and the highest rate of any UK region.
Nation.Cymru staff A study has found that more Welsh adults are self-medicating for anxiety and stress than in any other part of the UK. New data from the STADA Health Report 2026 has found 31 per cent of adults in Wales self-medicate for anxiety or stre
You might also wanna read
News Scan for Oct 12, 2021
cahfs.umn.edu·4y ago
Norwegian study finds 62% rise in mental health consultations driven by symptom-coded visits, not disorder diagnoses
A nationwide Norwegian register-based study (2010–2024, N=3,728,002) found that mental health consultation prevalence increased by 62% (from
jech.bmj.com·6d ago
GPs in England Express Concern About Over-Diagnosis of Mental Health Conditions
Hundreds of GPs across England have told the BBC they believe mental health problems are being over-diagnosed, with many doctors expressing
bbc.com·7mo ago
Pharmaceutical LSD (MM120) Shows Promise in Treating Generalized Anxiety Disorder in UCSF Clinical Trials
Researchers at UCSF are testing MM120, a pharmaceutical form of LSD, as a treatment for generalized anxiety disorder (GAD). The treatment ha
sciencedaily.com·3mo ago
Over one million children referred for mental healthcare - with anxiety the main reason
BBC·8d ago
The debate about whether the NHS should use magic mushrooms to treat depression
BBC·6mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.